Topical intranasal ioxaglate meglumine 39.3% and ioxaglate sodium 19.6% (Hexabrix) reduces the acute response to nasal challenge with allergen

  • Shilpa Vishwanath
  • , Fuad M. Baroody
  • , Mohamad R. Chaaban
  • , Marcella Detineo
  • , Kenneth H. Lasser
  • , Elliot C. Lasser
  • , Robert M. Naclerio

Research output: Contribution to journalArticlepeer-review

2 Scopus citations
Original languageEnglish (US)
Pages (from-to)219-221
Number of pages3
JournalJournal of Allergy and Clinical Immunology
Volume128
Issue number1
DOIs
StatePublished - Jul 2011
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this